Solvonis Therapeutics plc

We're delighted to feature in @thisismoney in today's @MailOnline SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism Covers our #AUD (SVN-001 & SVN-002) and #PTSD (SVN-SDN-14) prgrms 🔗 dailymail.co.uk/money/markets/… @proactive_x @ProfDavidNutt @AnthonyTennyson

Our CEO, @AnthonyTennyson, cuaght up with @ZaksTradersCafe earlier today to provide details on our recent progress in drug discovery for #PTSD and drug development for #AUD 👂have a listen! @Solvonis @ProfDavidNutt

Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS audioboom.com/posts/8762104-… @Solvonis @SolvonisTx

Hey @SolvonisTx followers - just a reminder - we've changed our twitter handle to @Solvonis - please follow us there for all our latest news Thanks!

Proud of our team + partners providing hope in PTSD treatment Follow our journey: @Solvonis solvonis.com/news/svn-sdn-1… @PTSDAlliance @PTSDUK @HeadwayUK @MindCharity @ProfDavidNutt #PTSD #MentalHealthAwareness #HopeThroughScience #NeuroInnovation

Positive results enable us to advance SVN-SDN-14 towards in vivo studies solvonis.com/news/svn-sdn-1… #clinicaltrials #TranslationalMedicine #DrugDevelopment #BiotechInvesting #LifeSciences @ProfDavidNutt @ClinicalTrialsGov @NatureMedicine @ScienceTM @Medscape

🚀 Positive preclinical results for SVN-SDN-14 in PTSD today Robust SERT, DAT, NET modulation Major milestone towards new PTSD therapies solvonis.com/news/svn-sdn-1… #PTSD #Biotech #DrugDiscovery #BiotechNews @FierceBiotech @EndpointsNews @NatureBiotech @ProfDavidNutt

Hey @SolvonisTx followers - we've changed our twitter handle to @Solvonis - please follow us there for all our latest news - thanks

PTSD isn’t just psychological — it’s neurological. Trauma affects serotonin, dopamine & noradrenaline pathways — disrupting mood, memory & stress response. Solvonis is targeting these systems. #PTSD #Neurobiology #CNSBiotech #Solvonis $SVNS

Over 300M people will experience #PTSD in their lifetime. Yet first-line treatments fall short. @SolvonisTx (LSE: SVNS) is developing new medicines for chronic, high-prevalence diseases like PTSD — where effective options remain limited. #MentalHealth #Solvonis

Solvonis (LSE: SVNS) is aligned with the neursychiatry market reset - ATAI, CMPS, MNMD, GHRS up 35–75% - Spravato hits $1.3B run rate - RFK Jr. calls for FDA reform $SVNS Clinically active, capital disciplined, CNS-focused #Biotech #CNS #AUD #PTSD #505b2 #SVNS #MentalHealth

Solvonis (LSE: SVNS) is advancing SVN‑002, a sublingual esketamine OTF, for mod.-to-severe AUD — ~66% of the 29M US cases - targeting 505b2 to Spravato Spravato, approved for TRD (~4–6M), hit $320M Q2 sales. J&J now guiding $3B–$3.5B peak. 📈 Bigger need. Clear precedent.

Solvonis is advancing SVN‑002 under the FDA’s 505(b)(2) pathway, referencing J&J’s $1B+ blockbuster Spravato®. SVN‑002 targets moderate-to-severe #AUD with a differentiated formulation for addiction clinics. #SVN002 #505b2 #Spravato #AddictionTreatment #Solvonis

AUD is the crisis we keep ignoring. 29.5M Americans meet criteria for AUD <5% get treatment. SVN‑002 is our neuroscience-led response: ✔ Novel esketamine therapeutic ✔ Clinic-based ✔ 505(b)(2) path, bridging to Spravato® #AUD #SVN002 #505b2 #AddictionTreatment #Solvonis

Congrats to @SolvonisTx Chair, Dennis Purcell, on landmark $1.9B @AbbVie–IGI deal As a Board Director at IGI, he played a key role in one of biotech’s biggest licensing agrmnts of 2025 🔹$700M upfront 🔹$1.225B in milestones 🔹Tiered royalties Proud to have him lead Solvonis

@SolvonisTx Chair Purcell joins Levin & Papadopoulos for a Lucid Capital Mrkts exclusive Three of biotechs most influential voices Must-watch conversation 📅 July 17 | 2PM ET 🎙️ Hosted by Elemér Piros Proud to have Dennis lead Solvonis #SVNS #Biotech #AIinBiotech #CNS

29.5M Americans meet criteria for #AlcoholUseDisorder. Just 5% receive treatment. Time for a new paradigm SVN‑002 is @SolvonisTx neuroscience-based response — designed for real-world clinical delivery in the #US #AUD #505b2 #AddictionTreatment #Solvonis

The burden of Severe AUD is staggering & urgent 📊 40M w/ AUD across US UK EU4 ➡️ ~13M w/ Severe AUD 💀 300K+ deaths/yr 💷 £27.4B/yr in England alone @Solvonis_Tx is advancing SVN‑001 — a Phase 3 treatment aiming to change this. 🔗 solvonis.com $SVNS #AUD #SVN001

Solvonis (LSE: $SVNS) is pleased to announce that @Singer_CM has initiated research coverage. The note, “Psyching Up for Success”, is authored by Dr. Karl Keegan, Head of Life Sciences Research. Avail to institutional investors now; public next week. londonstockexchange.com/news-article/S…

At Solvonis (LSE: SVNS), USPTO has allowed a core patent (No. 18/838,986) for novel #CNS compounds in our #AI-enabled discovery prgm -No objections -Indications: depression, stimulant use disorder -US exclusivity to ≥2043 $SVNS #Biotech #MentalHealth polaris.brighterir.com/public/graft_p…